Switzerland-based Arvelle Therapeutics, which was acquired by Italy’s Angelini earlier this year, today…
To continue reading The Pharma Letter please login ,   subscribe  or  claim a 7 day free trial subscription  and access exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space. Or, if you're only interested in reading the content about a specific topic (M&A, coronavirus/COVID-19, pricing, reimbursement and access, outsourcing, CRO and CMO, and regulation), then you can take our £10 per month channel subscription offer, which gives you access to all our news articles and in-depth content on this subject.

NICE recommends Angelini’s Ontozry for the treatment of focal-onset seizures

100% seizure reduction for ≥12 consecutive months occurred at some time during the study in 36% of the 240 patients(1)
Seizure reduction began as early as the first four weeks with XCOPRI treatment(1)
Concomitant ASM reductions contributed to higher retention of XCOPRI and lowered overall drug burden(2)
News provided by
Share this article
Share this article
PARAMUS, N.J., Oct. 12, 2021 /PRNewswire/ --  SK Life Science, Inc. , a subsidiary of SK Biopharmaceuticals Co., Ltd., an innovative global pharmaceutical company focused on developing treatments for central nervous system (CNS) disorders, announced that the results from two post-hoc analyses of the long-term, open-label, multicenter, Phase 3 safety study, C021, have been published online by the journal Epilepsia ( here  and here ). The two post-hoc analyses, which retrospectively collected data from a subset of 240 patients with focal seizures across 10 sites in the U.S., showed long-term efficacy and safety of XCOPRI, as well as the impact of adjustments to other baseline anti-seizure medications (ASMs). "The results of these two new post-hoc analyses provide evidence of the durable efficacy of XCOPRI, as many patients sustained 90% and 100% reductions of their seizures over the course of the entire maintenance period, lasting up to 40.2 months," said William E. Rosenfeld, MD, epileptologist/neurologist who performed the studies and was the principal investigator at the Comprehensive Epilepsy Care Center for Children and Adults in St. Louis, Missouri. "I am encouraged to see the high retention rates associated with XCOPRI. Many patients continued on XCOPRI and remained seizure free, while also reducing or discontinuing one or more concomitant ASMs. These analyses may provide clinicians with real-world insight on managing their patients' seizures, minimizing drug burden, while potentially reducing the side effects of concomitant ASMs associated with epilepsy treatment." Treatment with XCOPRI resulted in long-term seizure reduction with treatment response as early as four weeks1
Among the 240 patients who entered the titration period, responder rates of ≥50% were observed in 48% of patients during weeks one through four. Following the titration period, 214 patients entered the maintenance phase. Of these patients treated with XCOPRI, 13% (n=28/214) had no seizures and 40% (n=86/214) had a 90% or greater seizure frequency reduction during the entire maintenance phase lasting up to 40.2 months (median 29.5 months). Additionally, 74% (n=177/240) of patients remained on the drug throughout the entire analysis period (median 2.7 years) and 36% (n=87/240) of patients had 100% seizure reduction for ≥12 consecutive months at some time during the study. Concomitant ASM reductions contributed to higher retention of XCOPRI (cenobamate tablets) CV2
In an analysis studying the effect of adjusting concomitant ASMs with adjunctive XCOPRI, long-term responder rates were generally similar regardless of concomitant ASM usage, with approximately 75% of patients being ≥50% responders during the maintenance phase. Of patients who continued on XCOPRI, 25% were able to discontinue at least one concomitant ASM completely. Among those who were able to reduce concomitant ASM doses, overall drug burden was reduced, allowing for increased tolerability and retention. There were greater reductions in ASM dosages among those who remained on XCOPRI, compared to those who discontinued. In these post-hoc analyses, no new safety signals were identified, and the most common adverse events in ongoing XCOPRI patients were fatigue, dizziness, and somnolence. About Study C021
Study C021 was a large, multi-center, open-label Phase 3 study assessing the safety of cenobamate as adjunctive therapy in 1,340 adults (18-70 years old) with uncontrolled focal seizures taking 1-3 anti-seizure medications (ASMs). The objectives of the study included the characterization of the long-term safety of cenobamate and to understand how to best add cenobamate to regimens that included phenytoin or phenobarbital. In addition, the study was designed to determine the rate of DRESS in at least 1,000 patients taking cenobamate for at least 6 months, using a low starting dose and every other week titration; no cases of DRESS occurred in the study. Cenobamate was initiated at 12.5 mg/day and increased at 2-week intervals to 25, 50, 100, 150 and 200 mg/day. Further increases to 400 mg/day using bi-weekly 50 mg/day increments were allowed. About XCOPRI® (cenobamate tablets) CV
Cenobamate was discovered and developed by SK Biopharmaceuticals and SK life science. While the precise mechanism by which cenobamate exerts its therapeutic effect is unknown, it is believed to reduce repetitive neuronal firing by inhibiting voltage-gated sodium currents. It is also a positive allosteric modulator of the γ-aminobutyric acid (GABAA) ion channel. Cenobamate is approved in the United States as an anti-seizure medication (ASM) for the treatment of partial-onset seizures in adults and is available under the brand name XCOPRI® (cenobamate tablets) CV. Cenobamate can be combined with other ASMs or used alone. Cenobamate is approved in the European Union (EU) under the brand name ONTOZRY® for the adjunctive treatment of focal-onset (partial-onset) seizures with or without secondary generalization in adult patients with epilepsy who have not been adequately controlled despite a history of treatment with at least two anti-epileptic medicinal products. SK Biopharmaceuticals entered an exclusive licensing agreement with Arvelle Therapeutics to develop and commercialize cenobamate in Europe in early 2019. Angelini Pharma, which announced a definitive acquisition agreement to acquire Arvelle Therapeutics, is commercializing cenobamate in the EU and other countries in the European Economic Area (Switzerland and the United Kingdom). SK Biopharmaceuticals also has an exclusive licensing agreement with Ono Pharmaceutical to develop and commercialize cenobamate in Japan. IMPORTANT SAFETY INFORMATION AND INDICATION FOR XCOPRI® (cenobamate tablets) CV
DO NOT TAKE XCOPRI IF YOU:
Are allergic to cenobamate or any of the other ingredients in XCOPRI. Have a genetic problem (called Familial Short QT syndrome) that affects the electrical system of the heart. XCOPRI CAN CAUSE SERIOUS SIDE EFFECTS, INCLUDING:
Allergic reactions: XCOPRI can cause serious skin rash or other serious allergic reactions which may affect organs and other parts of your body like the liver or blood cells. You may or may not have a rash with these types of reactions. Call your healthcare provider right away and go to the nearest emergency room if you have any of the following: swelling of your face, eyes, lips, or tongue, trouble swallowing or breathing, a skin rash, hives, fever, swollen glands, or sore throat that does not go away or comes and goes, painful sores in the mouth or around your eyes, yellowing of your skin or eyes, unusual bruising or bleeding, severe fatigue or weakness, severe muscle pain, frequent infections, or infections that do not go away. Take XCOPRI exactly as your healthcare provider tells you to take it. It is very important to increase your dose of XCOPRI slowly, as instructed by your healthcare provider. QT shortening: XCOPRI may cause problems with the electrical system of the heart (QT shortening). Call your healthcare provider if you have symptoms of QT shortening including fast heartbeat (heart palpitations) that last a long time or fainting. Suicidal behavior and ideation: Antiepileptic drugs, including XCOPRI, may cause suicidal thoughts or actions in a very small number of people, about 1 in 500. Call your health care provider right away if you have any of the following symptoms, especially if they are new, worse, or worry you: thoughts about suicide or dying; attempting to commit suicide; new or worse depression, anxiety, or irritability; feeling agitated or restless; panic attacks; trouble sleeping (insomnia); acting aggressive; being angry or violent; acting on dangerous impulses; an extreme increase in activity and talking (mania); or other unusual changes in behavior or mood. Nervous system problems: XCOPRI may cause problems that affect your nervous system. Symptoms of nervous system problems include: dizziness, trouble walking or with coordination, feeling sleepy and tired, trouble concentrating, remembering, and thinking clearly, and vision problems. Do not drive, operate heavy machinery, or do other dangerous activities until you know how XCOPRI affects you. Do not drink alcohol or take other medicines that can make you sleepy or dizzy while taking XCOPRI without first talking to your healthcare provider. DISCONTINUATION:
Do not stop taking XCOPRI without first talking to your healthcare provider. Stopping XCOPRI suddenly can cause serious problems. Stopping seizure medicine suddenly in a patient who has epilepsy can cause seizures that will not stop (status epilepticus). DRUG INTERACTIONS:
XCOPRI may affect the way other medicines work, and other medicines may affect how XCOPRI works. Do not start or stop other medicines without talking to your healthcare provider. Tell healthcare providers about all the medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements. PREGNANCY AND LACTATION:
XCOPRI may cause your birth control medicine to be less effective. Talk to your health care provider about the best birth control method to use. Talk to your health care provider if you are pregnant or plan to become pregnant. It is not known if XCOPRI will harm your unborn baby. Tell your healthcare provider right away if you become pregnant while taking XCOPRI. You and your healthcare provider will decide if you should take XCOPRI while you are pregnant. If you become pregnant while taking XCOPRI, talk to your healthcare provider about registering with the North American Antiepileptic Drug (NAAED) Pregnancy Registry. The purpose of this registry is to collect information about the safety of antiepileptic medicine during pregnancy. You can enroll in this registry by calling 1-888-233-2334 or go to  www.aedpregnancyregistry.org . Talk to your health care provider if you are breastfeeding or plan to breastfeed. It is not known if XCOPRI passes into breastmilk. Talk to your healthcare provider about the best way to feed your baby while taking XCOPRI. COMMON SIDE EFFECTS:
The most common side effects in patients taking XCOPRI include dizziness, sleepiness, headache, double vision, and feeling tired. These are not all the possible side effects of XCOPRI. Tell your healthcare provider if you have any side effect that bothers you or that does not go away. For more information, ask your healthcare provider or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at  www.fda.gov/medwatch . DRUG ABUSE:
XCOPRI is a federally controlled substance (CV) because it can be abused or lead to dependence. Keep XCOPRI in a safe place to prevent misuse and abuse. Selling or giving away XCOPRI may harm others and is against the law. INDICATION:
XCOPRI is a prescription medicine used to treat partial-onset seizures in adults 18 years of age and older. It is not known if XCOPRI is safe and effective in children under 18 years of age. Please see additional patient information in the  Medication Guide . This information does not take the place of talking with your healthcare provider about your condition or your treatment. About Epilepsy  
Epilepsy is the fourth most common neurological disorder. There are approximately 3.4 million people living with epilepsy in the United States, with 150,000 news cases each year in the country.3,4 Epilepsy is characterized by recurrent, unprovoked seizures. The seizures in epilepsy may be related to a brain injury or a family tendency, but often the cause is completely unknown. Having seizures and epilepsy can affect one's safety, relationships, work, driving, and much more.5,6 People with epilepsy are at risk for accidents and other health complications, including falling, drowning, depression and sudden unexplained death in epilepsy (SUDEP).5,6 Despite the availability of many antiepileptic therapies, almost 40 percent of people with epilepsy are not able to achieve seizure freedom, meaning they have epilepsy that remains uncontrolled.7 
About SK Biopharmaceuticals Co., Ltd. and SK Life Science, Inc.  
SK Biopharmaceuticals and its U.S. subsidiary SK life science are global pharmaceutical companies focused on the research, development and commercialization of treatments for disorders of the central nervous system (CNS). The companies have a pipeline of eight compounds in development for the treatment of CNS disorders, including epilepsy. Additionally, SK Biopharmaceuticals is focused on the discovery of new treatments in oncology. For more information, visit SK Biopharmaceuticals' website at  www.skbp.com/eng  and SK life science's website at  www.SKLifeScienceInc.com . Both SK Biopharmaceuticals and SK life science are part of SK Group, one of the largest conglomerates in Korea. SK Inc., the parent company of SK Biopharmaceuticals, continues to enhance its portfolio value by executing long-term investments with a number of competitive subsidiaries in various business areas, including pharmaceuticals and life science, energy and chemicals, information and telecommunication, and semiconductors. In addition, SK Inc. is focused on reinforcing its growth foundations through profitable and practical management based on financial stability, while raising its enterprise value by investing in new future growth businesses. For more information, please visit  http://hc.sk.co.kr/en/ . XCOPRI® and ONTOZRY® are registered trademarks of SK Biopharmaceuticals Co., Ltd.
References 
Sperling M, Abou-Khalil B, Aboumatar S, et. al. Efficacy of cenobamate for uncontrolled focal seizures: post hoc analysis of a phase 3, multicenter, open-label study. https://onlinelibrary.wiley.com/doi/full/10.1111/epi.17091 . Published online October 11, 2021. Rosenfeld W, Abou-Khalil B, Aboumatar S, et. al. Post-hoc analysis of a phase 3, multicenter, open-label study of cenobamate for treatment of uncontrolled focal seizures: effects of dose adjustments of concomitant antiseizure medications. https://onlinelibrary.wiley.com/doi/full/10.1111/epi.17092 . Published online October 11, 2021. Epilepsy Foundation. Who Gets Epilepsy? https://www.epilepsy.com/learn/about-epilepsy-basics/who-gets-epilepsy . Accessed July 2021. Epilepsy Foundation. Epilepsy Statistics. https://www.epilepsy.com/learn/about-epilepsy-basics/epilepsy-statistics . Accessed July 2021. Epilepsy Foundation. Staying Safe. https://www.epilepsy.com/learn/seizure-first-aid-and-safety/staying-safe . Accessed July 2021. Epilepsy Foundation. Challenges with Epilepsy. https://www.epilepsy.com/learn/challenges-epilepsy . Accessed July 2021. Chen Z, Brodie MJ, Liew D, Kwan P. Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: a 30-year longitudinal cohort study. https://www.ncbi.nlm.nih.gov/pubmed/29279892 . Published online December 26, 2017. SOURCE SK Life Science, Inc.
×

09:00 ET
Epilepsia Publishes Two Post-hoc Analyses from Long-Term Study of XCOPRI® (cenobamate tablets) CV

The open-label extension of Study C013 demonstrated safety and tolerability in adults with focal seizures treated with cenobamate for a median duration of 6.25 years
News provided by
Share this article
Share this article
PARAMUS, N.J., July 20, 2021 /PRNewswire/ -- SK Life Science, Inc. , a subsidiary of SK Biopharmaceuticals Co., Ltd., an innovative global pharmaceutical company focused on developing treatments for central nervous system (CNS) disorders, announced that the results of the long-term, open-label extension (OLE) of a randomized, double-blind, placebo-controlled study of cenobamate (C013) have been published online by the journal Epilepsia. The OLE, which enrolled 149 adult patients who completed the 12-week C013 study, showed high rates of retention and demonstrated that adjunctive cenobamate was generally safe and well-tolerated long-term. Among the 149 enrolled patients, the median treatment duration was 6.25 years (200 mg median modal daily dose, range 50 to 400 mg). As of the data cut-off in July 2019, 57% (85/149) continued on cenobamate. "In this long-term evaluation with cenobamate, we observed high retention rates beyond six years in a real-life clinical setting in which patients received individualized doses of both cenobamate and other anti-seizure medications (ASMs)," said Jaqueline French, M.D, Professor of Neurology, NYU Langone Comprehensive Epilepsy Center, Director, Epilepsy Study Consortium, and Chief Medical and Innovation Officer, Epilepsy Foundation. "Because refractory epilepsy is a chronic, difficult to manage condition requiring ongoing treatment, the long-term retention rates represent an important and encouraging clinical outcome reflecting the safety, tolerability and effectiveness of cenobamate." Upon completing the 12-week, double-blind portion of Study C013, 149 patients entered the OLE taking cenobamate along with 1-3 additional ASMs. Based on a Kaplan-Meier analysis, the probability of continuing cenobamate for 6 years was 59%; among those who remained on cenobamate for at least 12 months (n=107), the probability of continuing for 6 years was 79%. Additionally, 54% (80/149) of patients taking cenobamate were able to discontinue one or more concomitant ASMs. Treatment discontinuation occurred in 64 patients, with the most common reasons being withdrawal by patient, (19%, 29/149), adverse events (10%, 15/149), and lack of efficacy (5%, 8/149). Over the entire duration of exposure, up to 7.8 years, the most common treatment emergent adverse events (TEAE) were dizziness (33%, 49/149), headache (27%, 40/149), and somnolence (22%, 32/149). TEAEs leading to discontinuation in >1% of patients were fatigue (1%, 2/149), ataxia (1%, 2/149), and memory impairment or amnesia (1%, 2/149). About Study C013
Study C013 was a multi-center, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of cenobamate 200 mg/day as an adjunctive therapy in adults (18-65 years old) with uncontrolled focal seizures. In the study, 222 patients were randomized (113 received cenobamate and 109 received placebo). Patients must have been taking 1-3 anti-seizure medications (ASMs) at stable doses for at least 12 weeks prior to randomization and continued taking concomitant ASMs at stable doses during the double-blind treatment period. The open label extension (OLE) of the study enrolled 149 patients from participating centers, including 76 patients originally randomized to cenobamate and 73 patients originally randomized to placebo during the double-blind period. The objective of the OLE was to examine long-term safety, tolerability, and retention rate of cenobamate as an adjunctive treatment. About Cenobamate
Cenobamate was discovered and developed by SK Biopharmaceuticals and SK life science. While the precise mechanism by which cenobamate exerts its therapeutic effect is unknown, it is believed to reduce repetitive neuronal firing by inhibiting voltage-gated sodium currents. It is also a positive allosteric modulator of the γ-aminobutyric acid (GABAA) ion channel. Cenobamate is approved in the United States as an anti-seizure medication (ASM) for the treatment of partial-onset seizures in adults and is available under the brand name XCOPRI® (cenobamate tablets) CV. Cenobamate can be combined with other ASMs or used alone. Cenobamate is approved in the European Union (EU) under the brand name ONTOZRY® for the adjunctive treatment of focal-onset (partial-onset) seizures with or without secondary generalization in adult patients with epilepsy who have not been adequately controlled despite a history of treatment with at least two anti-epileptic medicinal products. SK Biopharmaceuticals entered an exclusive licensing agreement with Arvelle Therapeutics to develop and commercialize cenobamate in Europe in early 2019. Angelini Pharma, which announced a definitive acquisition agreement to acquire Arvelle Therapeutics, is commercializing cenobamate in the European Union and other countries in the European Economic Area (Switzerland and the United Kingdom). SK Biopharmaceuticals also has an exclusive licensing agreement with Ono Pharmaceutical to develop and commercialize cenobamate in Japan. IMPORTANT SAFETY INFORMATION AND INDICATION FOR XCOPRI® (cenobamate tablets) CV
DO NOT TAKE XCOPRI IF YOU:
Are allergic to cenobamate or any of the other ingredients in XCOPRI. Have a genetic problem (called Familial Short QT syndrome) that affects the electrical system of the heart. XCOPRI CAN CAUSE SERIOUS SIDE EFFECTS, INCLUDING:
Allergic reactions: XCOPRI can cause serious skin rash or other serious allergic reactions which may affect organs and other parts of your body like the liver or blood cells. You may or may not have a rash with these types of reactions. Call your healthcare provider right away and go to the nearest emergency room if you have any of the following: swelling of your face, eyes, lips, or tongue, trouble swallowing or breathing, a skin rash, hives, fever, swollen glands, or sore throat that does not go away or comes and goes, painful sores in the mouth or around your eyes, yellowing of your skin or eyes, unusual bruising or bleeding, severe fatigue or weakness, severe muscle pain, frequent infections, or infections that do not go away. Take XCOPRI exactly as your healthcare provider tells you to take it. It is very important to increase your dose of XCOPRI slowly, as instructed by your healthcare provider. QT shortening: XCOPRI may cause problems with the electrical system of the heart (QT shortening). Call your healthcare provider if you have symptoms of QT shortening including fast heartbeat (heart palpitations) that last a long time or fainting. Suicidal behavior and ideation: Antiepileptic drugs, including XCOPRI, may cause suicidal thoughts or actions in a very small number of people, about 1 in 500. Call your health care provider right away if you have any of the following symptoms, especially if they are new, worse, or worry you: thoughts about suicide or dying; attempting to commit suicide; new or worse depression, anxiety, or irritability; feeling agitated or restless; panic attacks; trouble sleeping (insomnia); acting aggressive; being angry or violent; acting on dangerous impulses; an extreme increase in activity and talking (mania); or other unusual changes in behavior or mood. Nervous system problems: XCOPRI may cause problems that affect your nervous system. Symptoms of nervous system problems include: dizziness, trouble walking or with coordination, feeling sleepy and tired, trouble concentrating, remembering, and thinking clearly, and vision problems. Do not drive, operate heavy machinery, or do other dangerous activities until you know how XCOPRI affects you. Do not drink alcohol or take other medicines that can make you sleepy or dizzy while taking XCOPRI without first talking to your healthcare provider. DISCONTINUATION:
Do not stop taking XCOPRI without first talking to your healthcare provider. Stopping XCOPRI suddenly can cause serious problems. Stopping seizure medicine suddenly in a patient who has epilepsy can cause seizures that will not stop (status epilepticus). DRUG INTERACTIONS:
XCOPRI may affect the way other medicines work, and other medicines may affect how XCOPRI works. Do not start or stop other medicines without talking to your healthcare provider. Tell healthcare providers about all the medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements. PREGNANCY AND LACTATION:
XCOPRI may cause your birth control medicine to be less effective. Talk to your health care provider about the best birth control method to use. Talk to your health care provider if you are pregnant or plan to become pregnant. It is not known if XCOPRI will harm your unborn baby. Tell your healthcare provider right away if you become pregnant while taking XCOPRI. You and your healthcare provider will decide if you should take XCOPRI while you are pregnant. If you become pregnant while taking XCOPRI, talk to your healthcare provider about registering with the North American Antiepileptic Drug (NAAED) Pregnancy Registry. The purpose of this registry is to collect information about the safety of antiepileptic medicine during pregnancy. You can enroll in this registry by calling 1-888-233-2334 or go to  www.aedpregnancyregistry.org . Talk to your health care provider if you are breastfeeding or plan to breastfeed. It is not known if XCOPRI passes into breastmilk. Talk to your healthcare provider about the best way to feed your baby while taking XCOPRI. COMMON SIDE EFFECTS:
The most common side effects in patients taking XCOPRI include dizziness, sleepiness, headache, double vision, and feeling tired. These are not all the possible side effects of XCOPRI. Tell your healthcare provider if you have any side effect that bothers you or that does not go away. For more information, ask your healthcare provider or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at  www.fda.gov/medwatch . DRUG ABUSE:
XCOPRI is a federally controlled substance (CV) because it can be abused or lead to dependence. Keep XCOPRI in a safe place to prevent misuse and abuse. Selling or giving away XCOPRI may harm others and is against the law. INDICATION:
XCOPRI is a prescription medicine used to treat partial-onset seizures in adults 18 years of age and older. It is not known if XCOPRI is safe and effective in children under 18 years of age. Please see additional patient information in the  Medication Guide . This information does not take the place of talking with your healthcare provider about your condition or your treatment. About Epilepsy  
Epilepsy is the fourth most common neurological disorder. There are approximately 3.4 million people living with epilepsy in the United States, with 150,000 news cases each year in the country.1,2 Epilepsy is characterized by recurrent, unprovoked seizures. The seizures in epilepsy may be related to a brain injury or a family tendency, but often the cause is completely unknown. Having seizures and epilepsy can affect one's safety, relationships, work, driving, and much more.3,4 People with epilepsy are at risk for accidents and other health complications, including falling, drowning, depression and sudden unexplained death in epilepsy (SUDEP).3,4 Despite the availability of many antiepileptic therapies, almost 40 percent of people with epilepsy are not able to achieve seizure freedom, meaning they have epilepsy that remains uncontrolled.5 
About SK Biopharmaceuticals Co., Ltd. and SK Life Science, Inc.  
SK Biopharmaceuticals and its U.S. subsidiary SK life science are global pharmaceutical companies focused on the research, development and commercialization of treatments for disorders of the central nervous system (CNS). The companies have a pipeline of eight compounds in development for the treatment of CNS disorders, including epilepsy. Additionally, SK Biopharmaceuticals is focused on the discovery of new treatments in oncology. For more information, visit SK Biopharmaceuticals' website at  www.skbp.com/eng  and SK life science's website at  www.SKLifeScienceInc.com . Both SK Biopharmaceuticals and SK life science are part of SK Group, one of the largest conglomerates in Korea. SK Inc., the parent company of SK Biopharmaceuticals, continues to enhance its portfolio value by executing long-term investments with a number of competitive subsidiaries in various business areas, including pharmaceuticals and life science, energy and chemicals, information and telecommunication, and semiconductors. In addition, SK Inc. is focused on reinforcing its growth foundations through profitable and practical management based on financial stability, while raising its enterprise value by investing in new future growth businesses. For more information, please visit  http://hc.sk.co.kr/en/ . XCOPRI® and ONTOZRY® are registered trademarks of SK Biopharmaceuticals Co., Ltd.
References 
Epilepsy Foundation. Epilepsy Statistics. https://www.epilepsy.com/learn/about-epilepsy-basics/epilepsy-statistics . Accessed July 2021
Epilepsy Foundation. Staying Safe. https://www.epilepsy.com/learn/seizure-first-aid-and-safety/staying-safe . Accessed July 2021. Epilepsy Foundation. Challenges with Epilepsy. https://www.epilepsy.com/learn/challenges-epilepsy . Accessed July 2021. Chen Z, Brodie MJ, Liew D, Kwan P. Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: a 30-year longitudinal cohort study. https://www.ncbi.nlm.nih.gov/pubmed/29279892 . Published online December 26, 2017. SOURCE SK Life Science, Inc.
Related Links

09:00 ET
Long-Term Safety and Tolerability of XCOPRI® (cenobamate tablets) CV Published in Epilepsia

July 06, 2021 05:00 AM Eastern Daylight Time
UTRECHT, The Netherlands--( BUSINESS WIRE )-- AM-Pharma B.V. , an emerging leader focused on developing therapeutics for severe medical conditions, today announced the appointment of Mark Altmeyer, MBA, as Chairman of its Supervisory Board. Mr. Altmeyer is a highly successful biopharma executive with decades of relevant strategic, operational, and commercial experience. As Chairman of AM-Pharma’s Supervisory Board, Mr. Altmeyer will provide important guidance as the Company expands its global clinical development program and identifies possible future pipeline initiatives for treating serious diseases. Martijn Kleijwegt, MSc, previous Chairman, will remain a member of the AM-Pharma board. “Mark has an extensive track record of leading biotechnology companies through strategic periods of growth,” said Erik van den Berg, CEO at AM-Pharma. “As we continue to execute our ongoing pivotal Phase III REVIVAL study and begin to evaluate additional therapeutic opportunities for ilofotase alfa, we are excited to welcome Mark as chairman to our supervisory board and look forward to his contributions.”
“AM-Pharma has proven its ability to bring an innovative drug candidate into a global pivotal study in a life-threatening indication that is in need of new therapeutic options,” added Mark Altmeyer, Chairman of AM-Pharma’s Supervisory Board. “As the Company is moving into the next stage of growth, we are identifying opportunities to expand the potential of ilofotase alfa in additional therapeutic areas as we begin preparations for the potential commercial launch in sepsis-associated acute kidney injury. I look forward to guiding AM-Pharma during this exciting time in the Company’s evolution and supporting the team to achieve our mission of helping patients with severe diseases.”
Prior to joining AM-Pharma’s Supervisory Board, Mark Altmeyer was founder, President and Chief Executive Officer at Arvelle Therapeutics, in addition to serving as Executive Director of Arvelle’s Board of Directors. At Arvelle, he led the development of the company until its acquisition by Angelini for USD 1 billion. In advance of that transaction, he established Arvelle’s global headquarters in Switzerland, secured USD 200 million initial funding and built the European team to over 100 employees in under two years. Before Arvelle, Mark served as President and Chief Commercial Officer at Axovant Sciences, where he was responsible for establishing Axovant’s global commercial capabilities and launch preparations for various pipeline products. Earlier in his career, Mark served as President and CEO at Otsuka America Pharmaceutical, leading the transformation into a successful commercial organization, doubling total revenues from USD 2.5 billion to nearly 5 billion in five years. Mark held senior commercial and business development positions at Bristol-Myers Squibb, Cetus Corporation and Bristol Labs in the United States. He holds an MBA from Harvard Graduate School of Business and a BA in economics from Middlebury College. About AM-Pharma
AM-Pharma's purpose is to save and improve the lives of patients confronted with severe medical conditions. Our initial focus is sepsis-associated acute kidney injury, the cause of death for hundreds of thousands of people hospitalized each year. Our proprietary compound, ilofotase alfa, has the potential to become the first treatment for sepsis-associated acute kidney injury and is now in a global pivotal Phase III clinical trial. We are a dedicated team driven to bring treatment options to severely ill patients, their families and acute care professionals. Find out more about us online at: www.am-pharma.com
- ENDS -

AM-Pharma Appoints Mark Altmeyer as Chairman of its Supervisory Board

AM-Pharma Appoints Mark Altmeyer as Chairman of its Supervisory Board
Utrecht, The Netherlands, 6 July, 2021 – AM-Pharma B.V. , an emerging leader focused on developing therapeutics for severe medical conditions, today announced the appointment of Mark Altmeyer, MBA, as Chairman of its Supervisory Board. Mr. Altmeyer is a highly successful biopharma executive with decades of relevant strategic, operational, and commercial experience. As Chairman of AM-Pharma’s Supervisory Board, Mr. Altmeyer will provide important guidance as the Company expands its global clinical development program and identifies possible future pipeline initiatives for treating serious diseases. Martijn Kleijwegt, MSc, previous Chairman, will remain a member of the AM-Pharma board. “Mark has an extensive track record of leading biotechnology companies through strategic periods of growth,” said Erik van den Berg, CEO at AM-Pharma. “As we continue to execute our ongoing pivotal Phase III REVIVAL study and begin to evaluate additional therapeutic opportunities for ilofotase alfa, we are excited to welcome Mark as chairman to our supervisory board and look forward to his contributions.”
“AM-Pharma has proven its ability to bring an innovative drug candidate into a global pivotal study in a life-threatening indication that is in need of new therapeutic options,” added Mark Altmeyer, Chairman of AM-Pharma’s Supervisory Board. “As the Company is moving into the next stage of growth, we are identifying opportunities to expand the potential of ilofotase alfa in additional therapeutic areas as we begin preparations for the potential commercial launch in sepsis-associated acute kidney injury. I look forward to guiding AM-Pharma during this exciting time in the Company’s evolution and supporting the team to achieve our mission of helping patients with severe diseases.” 
Prior to joining AM-Pharma’s Supervisory Board, Mark Altmeyer was founder, President and Chief Executive Officer at Arvelle Therapeutics, in addition to serving as Executive Director of Arvelle’s Board of Directors. At Arvelle, he led the development of the company until its acquisition by Angelini for USD 1 billion. In advance of that transaction, he established Arvelle’s global headquarters in Switzerland, secured USD 200 million initial funding and built the European team to over 100 employees in under two years. Before Arvelle, Mark served as President and Chief Commercial Officer at Axovant Sciences, where he was responsible for establishing Axovant’s global commercial capabilities and launch preparations for various pipeline products. Earlier in his career, Mark served as President and CEO at Otsuka America Pharmaceutical, leading the transformation into a successful commercial organization, doubling total revenues from USD 2.5 billion to nearly 5 billion in five years. Mark held senior commercial and business development positions at Bristol-Myers Squibb, Cetus Corporation and Bristol Labs in the United States. He holds an MBA from Harvard Graduate School of Business and a BA in economics from Middlebury College. About AM-Pharma
AM-Pharma’s purpose is to save and improve the lives of patients confronted with severe medical conditions. Our initial focus is sepsis-associated acute kidney injury, the cause of death for hundreds of thousands of people hospitalized each year. Our proprietary compound, ilofotase alfa, has the potential to become the first treatment for sepsis-associated acute kidney injury and is now in a global pivotal Phase III clinical trial. We are a dedicated team driven to bring treatment options to severely ill patients, their families and acute care professionals. Find out more about us online at: www.am-pharma.com

Arvato is a global provider of business process outsourcing (BPO) services, supporting business/B2B clients across a wide range of industries in maintaining successful customer relations by designing and delivering customized/bespoke solutions in nearly 40 countries. Its wide range of services includes data management, customer services, customer relations services, supply chain management, digital distribution, financial services, professional and customized IT services, and all services related to the creation and distribution of printed materials and digital storage media.

Arvato Systems

Arvelle Therapeutics International GmbH entered into a partnership with Arvato Systems for the serialization of `` Cenobamate '' , a potential anti-seizure investigational drug in Europe .

Arvelle Therapeutics implements serialization solution "Arvato CSDB
Arvelle Therapeutics Committed to Patients and Healthcare Professionals through the Implementation of the IT Solution "Arvato CSDB".

SK Biopharmaceuticals (KRX: 326030), part of SK Group, is focused on the research and development of treatments for disorders of the central nervous system (CNS) and cancer. SK Biopharmaceuticals has a pipeline of compounds in development for the treatment of CNS disorders including epilepsy, sleep disorder, and attention deficit hyperactivity disorder, among others.

SK Biopharmaceuticals

Durbin supplies pharmaceuticals and medical equipment to healthcare manufacturers.

Durbin

Axovant

HealthInvest Equity Partners

CHL Medical Partners

J.H. Whitney

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Biopharma Tech

Acquired

Arvelle Therapeutics seeks to bring CNS products to patients suffering from neurological conditions.On January 4th, 2021, Arvelle Therapeutics was acquired by Angelini Pharma at a valuation of $960M.

Name	Gregory Weinhoff
Work History	Axovant, HealthInvest Equity Partners, CHL Medical Partners, and J.H. Whitney
Title	Founder
Status	Current

Wells Fargo Success Story

3M Success Story

Platform Overview

Arvelle Therapeutics

Executives

Arvelle Therapeutics Management Team

1 Team Member

Discover the right solution for your team